Pakistan hit by nationwide blackout

ISLAMABAD: Pakistan was hit by a nationwide blackout for more than two hours after the breakdown of a major plant caused power stations to stop working across the country, officials said Monday.

While power cuts are common in Pakistan due to chronic underinvestment in infrastructure, outages across the whole country are rare.

Late Sunday's blackout occurred when the HUBCO plant in southwestern Baluchistan province, which generates 1,200 megawatts a day of electricity, developed a technical fault, said official Rai Sikandar.

That breakdown prompted a "cascading effect" which caused plants nationwide to shut down, said the water and power ministry official.

"It was a technical fault in one of our power plants and not in the national grid," he insisted, adding that electricity was gradually being restored across Pakistan after it remained off for more than two hours.

Another ministry official said power should be back on across the country within two hours.

He said that all 24 power stations in the capital Islamabad were working again and electricity was being restored in parts of all the country's four provinces.

"1,200 megawatts of electricity is back in the national grid with the restoration of different power stations," said the official.

He added an inquiry would look into the causes of the technical fault at HUBCO. "It would be pre-mature at this stage to speculate about the nature of the fault that caused the plant to fail."

- AFP/jc

Read More..

Riyaz Bhatkal: Shy student to terror mastermind

MUMBAI: Seventeen-year-old Riyaz Shahbandri from Kurla was a shy civil engineering student at Nagpada's Saboo Siddik polytechnic in 1993. He would maintain a low profile and hardly participated in any college events. However, girls found his chocolate-boy looks appealing. Two decades later, he began making headlines as Riyaz Bhatkal, a suspected terrorist who has killed more people than the feared Dawood Ibrahim or the hanged Pakistani terrorist Ajmal Kasab—more than 344 killed from 15 bomb blasts. Still elusive, today he is the most dreaded face of the banned terror outfit Indian Mujahideen.

Born in 1976 as Riyaz Ismail Shahbandri in Bhatkal village of Karnataka, he came to be known as Roshan Jamal, while staying at the 60-year-old, two-storey building Qadir Mansion in Kurla here. Today his family owns two rooms in the building, which have been rented out as they wanted to stay away from the police who would often land up at their place inquiring about his whereabouts. His father, Ismail, had shifted from Karnataka to Mumbai for setting up a purse-making business much before Riyaz was born. Despite obtaining a degree in civil engineering, Riyaz couldn't find a job and began helping his father in his business. By then, his elder brother Iqbal had joined a local developer's firm as a civil engineer.

In 2001, Riyaz fell in love with a girl from Kurla but his family disapproved of the relationship and he was finally married to Nashua, the daughter of a Bhatkal-based businessman. A few months before his wedding, he came in touch with the Kurla unit of Students' Islamic Moment of India (SIMI). When he became a member of the outfit, it was already divided into two factions, extremists and the moderates. Riyaz preferred to stay with the first group. While the outfit was banned and its members arrested, he managed to evade the police. Soon he started preaching the SIMI ideology and was considered as a key figure among his associates. At the same time, Riyaz came in touch with local goons and started extorting money from traders in order to fund the activities of SIMI. "In 2002, he allegedly gave supari to kill the owner of Deepak Farsan in Kurla. The shooters killed the owner's bodyguard and Riyaz was never arrested," said an investigator of the case.

A city crime branch official said, "A year later, he entered Pakistan illegally and got training in operating fire arms and assembling explosives at a Lashkar-e-Taiba (LeT) camp. In 2004, along with Atif Ameen (who was later killed in the Batla House encounter in 2008), Sadiq Asrar Shaikh (who is behind bars in Mumbai), Subhan Qureishi alias Tauqeer and Yasin Bhatkal (both absconding), he conducted his first training for Indian men at Jolly Beach, a farm house in Bhatkal. Yasin, though hailing from Bhatkal, is not related to Riyaz. In 2005, the quintet executed their first terror blast at Sankat Mochan temple in Uttar Pradesh. While Riyaz provided the explosives, Tauqeer and Shaikh recruited the men. This was the time the group decided to name itself Indian Mujahideen (IM). Cops were unaware of its existence. Iqbal too had got influenced by the extremist ideology. He was one of the founder members of the IM.

"Soon after executing the bombings at the court premises in Lucknow, Varanasi and Faizabad on November 23, 2007, IM sent its first email to a news channel, claiming responsibility," the charge sheet on these blasts reads. In 2008, IM carried out bombings in Bangalore and Ahmedabad and for the first time Riyaz's name cropped up during the probe. He had conducted a seven-day training session for new recruits at Bhatkal prior to the blasts." After police started visiting Bhatkal frequently in search of him, Riyaz escaped to Pakistan in 2008 via Bangladesh. That was the last time his family saw him," a senior ATS officer added. Meanwhile, his father was last spotted in Mumbai on April 16, 2008, when he had gone to collect rent for his two rooms in Qadir Mansion.

In March 2010, Riyaz travelled to Colombo and met Yasin Bhatkal, Mohsin Chaudhry and Mirza Himayat Bain to plan Pune's German Bakery bomb blast. In July 2011, a red corner notice was issued against Riyaz in connection with the 2008 Bangalore blast. The chargesheet in Mumbai's July 13, 2011, triple blast cases said that "the entire criminal conspiracy was hatched by Riyaz and Yasin Bhatkal", who are "the chief cogs of the notorious" IM. The banned terrorist group, it adds, was created by Pakistani spy agency ISI "to spread terror in India". Riyaz and his brother Iqbal Bhatkal "operate from Pakistan" and impart instructions via electronic means to their associates based here through Yasin. According to forensic reports, Trinitrotoluene (TNT), ammonium nitrate and petroleum oil were used in the Mumbai bomb blasts.

This is the story as narrated by Riyaz's proteges, neighbors, friends and police. However, no one knows Riyaz's side of the story.

Riyaz Bhatkal's bloody trail:

Oct 29, 2005: Paharganj, Sarojini Nagar and Gopal Nagar in Delhi, killed 62

March 7, 2006: Sankat Mochan temple, Kashi Viswanath temple in Varanasi, killed 28

Nov 24, 2006: Faizabad, Lucknow and Varanasi courts

May 25, 2007: Gorakhpur market

Aug 25, 2007: Lumbini Park and Gokul Chat in Hyderabad, killed 42

May 23, 2008: Jaipur, killed 80

July 24, 2008: Bangalore, killed 02

July 25, 2008: Ahmedabad serial explosions, killed 56

July 26, 2008: Surat (bombs defused)

Sept 13, 2008: Delhi, killed 30

Feb 13, 2010: Pune German Bakery blast, killed 17

July 13, 2011: Mumbai triple blasts, killed 27

August 1, 2012: Pune serial bomb blasts

Total killed: 344

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Fiery Last-Lap Daytona Crash Injures 15 Fans

A fiery last-lap crash at the Daytona International Speedway injured a number of spectators today, who were seen being carried away from the stands on stretchers.

Fifteen spectators were taken to the hospital, according to ESPN, with one on the way to surgery with head trauma.

The 12-car crash happened moments before the end of the Nationwide race, and on the eve of the Daytona 500, one of NASCAR's biggest events.

The crash was apparently triggered when driver Regan Smith's car, which was being tailed by Brad Keselowski on his back bumper, spun to the right and shot up the track. Smith had been in the lead and said after the crash he had been trying to throw a "block."

Rookie Kyle Larson's car slammed into the wall that separates the track from the grandstands, causing his No. 32 car to go airborne and erupt in flames.

When a haze of smoke cleared and Larson's car came to a stop, he jumped out uninjured.

His engine and one of his wheels were sitting in a walkway of the grandstand.

"I was getting pushed from behind," Larson told ESPN. "Before I could react, it was too late."

Driver Michael Annett was taken to the hospital after he slammed head-on into a barrier during the chaos. NASCAR officials told ESPN the driver was awake and alert.

Tony Stewart pulled out the win, but in victory lane, what would have been a celebratory mood was tempered by concern for the injured fans.

"We've always known this is a dangerous sport," Stewart said. 'But it's hard when the fans get caught up in it."

Read More..

Berlusconi slams Europe's 'lords of austerity'

ROME: Italy's Silvio Berlusconi on Saturday said Europe's "lords of austerity" had tried to get rid of him, speaking in apparent breach of rules for candidates to stay silent the day before elections.

"I contradicted the lords of austerity who are now trying to get rid of me," Berlusconi was quoted by the ANSA news agency as saying in Milan in an interview with Greek television.

Leftist candidate Antonio Ingroia asked for sanctions against the billionaire tycoon but Berlusconi's office said the interview had been given only with the explicit agreement that it be released on Monday after polls close.

The comments were then widely quoted by Italian media.

In the interview, the scandal-tainted Berlusconi said outgoing prime minister Mario Monti was "subservient and always on his knees in front of Mrs Merkel (German Chancellor Angela Merkel) and now she does not want to lose him".

"The same thing would happen with (centre left leader and poll favourite Pier Luigi) Bersani. But I would give her a run for her money," he said.

"Austerity increases the public debt and lead to a recessionary spiral that pushes up unemployment and can result in the loss of social calm," he added.

Berlusconi, who is currently a defendant in two trials for tax fraud and for having sex with an underage prostitute, also said prosecutors were "a worse mafia than the Sicilian mafia".

Italians take to the polls on Sunday and Monday, Berlusconi expected to come a close second after Bersani.

- AFP/jc

Read More..

Stuck to rubber, terrorists let go of gun

AGARTALA: Ranjit Debbarma still remembers the day 11 years ago when, as an area commander with banned terrorist group NLFT, he trekked for two months -- from the Jampui hills to Rangamurra and then to border areas of Bangladesh before finally reaching Burma -- to carry back Ak 47, 56, M 16 and SK guns for the insurgency back home in Tripura.

Today, though, the 37-year-old can be seen going from one rubber tree to another, collecting latex and talking to his labourers in the plantation at Jarul Bachai, about 13 km from Agartala. His daughter is in an English school and he now wants to buy a motorbike so that it's easier for him to drop her to class every day.

"We were safe in the camps of both Bangladesh and Burma then," the National Liberation Front of Tripura guerrilla says, squinting under an unusually bright February sun. "But I now realize that we were misled. I spent six years of my life carrying arms and collecting protection money from terrified people. We were told Tripura should be for its indigenous people and that even our king has been dispossessed by the Bengalis who came here much after we did. We had taken this falsehood as religion. Rubber is the only thing that matters to me now, my only god."

Tripura's burgeoning rubber trade, which has grown from a cultivable area of just 3500 hectares in 1982 to a massive 57,620 hectares in 2012, has changed the life of Debbarma and hundreds of other former militants like him in Tripura. A senior Rubber Board official puts the number at 754. "I have personally trained 60 of them," he says. "This has been a major rehabilitation effort, and I would go to the extent of saying it helped curb insurgency. People like Debbarma will always be grateful to the CPM government for this, if nothing else."

A state done in by lack of connectivity with the rest of the country and an even greater absence of industry, Tripura has been quick to latch on to rubber, spreading fear in many that the way things are going no one will be cultivating anything else in the near future. "Now it is second only to Kerala in terms of production," says Madhu Chatterjee, who has around 100 kanis (6.25 kanis make a hectare) devoted to the crop. "More than 50,000 farmers are involved in this these days as the returns are very high - a kg goes for Rs 210 on an average and profits can be more than Rs 100 - and the state has just the kind of weather that suits this thing. Even those with very little money can invest in it."

A rubber board official, who doesn't want to be named, says that the government is still reluctant to come clean regarding the names or numbers of former rebels who have either been given money to invest in rubber or have been provided small patches of land. "Most of those who came for training used their nom de guerre and went away leaving behind their nom de guerre," he says, adding, "I think we are better off not knowing who they really were, how many they killed and how many lives they ruined. That was the quid pro quo - give us a new life and we'll leave you in peace."

Back in Debbarma's field, he says he knows at least ten others like him who are leading normal lives, stuck to latex, and working as farmers and plantation managers. "If every government helps terrorists in this way, few will pick up the gun,'' he says. "After all, it is only us poor who because of hunger and penury are easy targets for recruitment. You can brainwash easily a man with no food on his table."

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Jodi Arias' Friends Believe in Her Innocence

Accused murderer Jodi Arias believes she should be punished, but hopes she will not be sentenced to death, two of her closest friends told ABC News in an exclusive interview.

Ann Campbell and Donavan Bering have been a constant presence for Arias wth at least one of them sitting in the Phoenix, Ariz., courtroom along with Arias' family for almost every day of her murder trial. They befriended Arias after she first arrived in jail and believe in her innocence.

Arias admits killing her ex-boyfriend Travis Alexander and lying for nearly two years about it, but insists she killed Alexander in self defense. She could face the death penalty if convicted of murder.

Jodi Arias Testimony: Prosecution's Cross-Examination Watch Video

Jodi Arias Remains Calm Under Cross-Examination Watch Video

Jodi Arias Doesn't Remember Stabbing Ex-Boyfriend Watch Video

Nevertheless, she is aware of the seriousness of her lies and deceitful behavior.

The women told ABC News that they understand that Arias needs to be punished and Arias understands that too.

"She does know that, you know, she does need to pay for the crime," Campbell said. "But I don't want her to die, and I know that she has so much to give back."

Catching Up on the Trial? Check Out ABC News' Jodi Arias Trial Coverage

The lies that Arias admits she told to police and her family have been devastating to her, Bering said.

""She said to me, 'I wish I didn't have to have lied. That destroyed me,'" Donovan said earlier this week. "Because now when it's so important for her to be believed, she has that doubt. But as she told me on the phone yesterday, she goes, 'I have nothing to lose.' So all she can do is go out there and tell the truth."

During Arias' nine days on the stand she has described in detail the oral, anal and phone sex that she and Alexander allegedly engaged in, despite being Mormons and trying to practice chastity. She also spelled out in excruciating detail what she claimed was Alexander's growing demands for sex, loyalty and subservience along with an increasingly violent temper.

Besides her two friends, Arias' mother and sometimes her father have been sitting in the front row of the courtroom during the testimony. It's been humiliating, Bering said.

"She's horrified. There's not one ounce of her life that's not out there, that's not open to the public. She's ashamed," she said.

Read More..

Rockets hit Aleppo, killing at least 29: monitor

BEIRUT (Reuters) - Rockets struck eastern districts of Aleppo, Syria's biggest city, on Friday, killing at least 29 people and trapping a family of 10 in the ruins of their home, activists in the city said.

"There are families buried under the rubble," said an activist called Baraa al-Youssef, speaking by Skype after visiting the scene in his Ard al-Hamra neighborhood.

"Nothing can describe it, it's a horrible sight."

Video footage posted by several activists showed a burning building and people carrying the wounded to cars to be ferried to hospital. It was hard to gauge the scale of the damage in the night-time footage but rubble was clearly visible on the ground.

Rami Abdulrahman of the British-based Syrian Observatory for Human Rights said three explosions shook Aleppo and reported at least 29 people had been killed. Another 150 were wounded, he said, and the final death toll was likely to be higher.

Youssef said 30 houses were destroyed by a single rocket.

On Tuesday activists said at least 20 people were killed when a large missile of the same type as Russian-made Scuds hit the rebel-held district of Jabal Badro.

(Reporting by Mariam Karouny and Dominic Evans; Editing by Stephen Powell)

Read More..

Pope to quit Twitter after stepping down: Vatican Radio

VATICAN CITY: The pope's official Twitter account, which has more than two million followers in nine languages, will close next week when Benedict XVI leaves office, Vatican Radio said Friday.

After a high-profile launch on December 12 under the name @pontifex, the pontiff's online musings quickly attracted over 1.5 million followers in English. Around a million other users of the site subscribe to his feeds in Italian, Spanish, German, French, Portuguese, Polish, Arab and even Latin and a Chinese account had been planned.

"It seemed unimaginable one could continue to use a communication tool that is so popular and powerful during the Sede Vacante (Vacant Seat) period," Vatican Radio said.

The leader of the world's 1.2 billion Catholics is expected to post his final tweet on February 27, when he will bid a farewell to ordinary Catholics at a general audience in St Peter's Square.

The account will then be closed on February 28 when Benedict formally steps down as pope, according to Vatican Radio.

No clear favourite has emerged yet to succeed Benedict but several cardinals tipped as possible candidates, including American Timothy Dolan, Odilo Scherer from Brazil and Gianfranco Ravasi and Angelo Scola from Italy, who are active Twitter users within the Church.

Benedict's bold move to become the first pope to join the Twittersphere sparked heated debate at the Vatican and within the Church. Supporters said it was a useful way to reach a younger generation, but some observers were dismayed to see that his pious posts invited a stream of mockery.

- AFP/jc

Read More..